These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 25264215

  • 21. N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model.
    Zhou X, Ono H, Ono Y, Frohlich ED.
    J Hypertens; 2002 May; 20(5):993-1000. PubMed ID: 12011661
    [Abstract] [Full Text] [Related]

  • 22. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases.
    Kojima S, Shida M, Yokoyama H.
    Hypertens Res; 2004 Jun; 27(6):379-85. PubMed ID: 15253102
    [Abstract] [Full Text] [Related]

  • 23. Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection.
    Miwa Y, Tsuchihashi T, Ohta Y, Tominaga M, Kawano Y, Sasaguri T, Ueno M, Matsuoka H.
    Clin Exp Hypertens; 2010 Jun; 32(6):400-5. PubMed ID: 20828221
    [Abstract] [Full Text] [Related]

  • 24. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M.
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Effect of benidipine hydrochloride, a long-acting T-type calcium channel blocker, on blood pressure and renal function in hypertensive patients with diabetes mellitus. Analysis after switching from cilnidipine to benidipine.
    Seino H, Miyaguchi S, Yamazaki T, Ota S, Yabe R, Suzuki S.
    Arzneimittelforschung; 2007 Aug; 57(8):526-31. PubMed ID: 17915639
    [Abstract] [Full Text] [Related]

  • 27. Comparison between L-type and N/L-type calcium channel blockers in the regulation of home blood-pressure variability in elderly hypertensive patients.
    Nozato S, Yamamoto K, Nozato Y, Takeda M, Hongyo K, Takeya M, Akasaka H, Takami Y, Takeya Y, Sugimoto K, Ito N, Rakugi H.
    Hypertens Res; 2018 Apr; 41(4):290-298. PubMed ID: 29449705
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease.
    Kanaoka T, Tamura K, Wakui H, Ohsawa M, Azushima K, Uneda K, Kobayashi R, Fujikawa T, Tsurumi-Ikeya Y, Maeda A, Yanagi M, Toya Y, Umemura S.
    Int J Mol Sci; 2013 Aug 16; 14(8):16866-81. PubMed ID: 23959116
    [Abstract] [Full Text] [Related]

  • 30. Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine.
    Tsuchihashi T, Ueno M, Tominaga M, Kajioka T, Onaka U, Eto K, Goto K.
    Clin Exp Hypertens; 2005 Nov 16; 27(8):583-91. PubMed ID: 16303635
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria.
    Katayama K, Nomura S, Ishikawa H, Murata T, Koyabu S, Nakano T.
    Kidney Int; 2006 Jul 16; 70(1):151-6. PubMed ID: 16710356
    [Abstract] [Full Text] [Related]

  • 33. Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats.
    Aritomi S, Harada E, Sugino K, Nishimura M, Nakamura T, Takahara A.
    Clin Exp Pharmacol Physiol; 2015 Apr 16; 42(4):344-52. PubMed ID: 25582553
    [Abstract] [Full Text] [Related]

  • 34. The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome.
    Konda T, Enomoto A, Matsushita J, Takahara A, Moriyama T.
    Nephron Physiol; 2005 Apr 16; 101(1):p1-13. PubMed ID: 15886499
    [Abstract] [Full Text] [Related]

  • 35. Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy.
    Sasaki H, Saiki A, Endo K, Ban N, Yamaguchi T, Kawana H, Nagayama D, Ohhira M, Oyama T, Miyashita Y, Shirai K.
    J Atheroscler Thromb; 2009 Oct 16; 16(5):568-75. PubMed ID: 19749494
    [Abstract] [Full Text] [Related]

  • 36. Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes.
    Shigihara T, Sato A, Hayashi K, Saruta T.
    Hypertens Res; 2000 May 16; 23(3):219-26. PubMed ID: 10821130
    [Abstract] [Full Text] [Related]

  • 37. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T, Japanese Lasartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators.
    Clin Exp Nephrol; 2003 Sep 16; 7(3):221-30. PubMed ID: 14586719
    [Abstract] [Full Text] [Related]

  • 38. Effects of cilnidipine on sympathetic nerve activity and cardiorenal function in hypertensive patients with type 2 diabetes mellitus: association with BNP and aldosterone levels.
    Tanaka M, Sekioka R, Nishimura T, Ichihara A, Itoh H.
    Diabetes Res Clin Pract; 2014 Dec 16; 106(3):504-10. PubMed ID: 25458339
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Effects of calcium channel antagonists on left ventricular hypertrophy and diastolic function in patients with essential hypertension.
    Takami T, Shigematsu M.
    Clin Exp Hypertens; 2003 Nov 16; 25(8):525-35. PubMed ID: 14649310
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.